

REMARKS


Claim 1 has been canceled. Claim 2 has been rewritten in independent form. Claims 3 to 7 have been amended to depend from Claim 2. No new matter has been added.

Claims 1-7 have been rejected under 35 USC 112, first paragraph, as not enabling for the prevention of neurological and vascular disorders. Claim 1 has been canceled. Claim 2 has been rewritten in independent form and does not refer to "prevention". Claims 3-7 have been amended to depend from Claim 2. The above amendments overcome the 112 rejection.

Claims 1 and 5-7 have been rejected under 35 USC 102(b) as anticipated by WO 03/057165 to Netzer. Claim 1 has been canceled. Claims 5 to 7 have been amended to no longer depend from claim 1, but now depend from claim 2. Claim 2 was not rejected by the Examiner as anticipated by the Netzer reference. Claim 2 discloses a method of treatment using compounds of formula (1). The compounds disclosed in the Netzer reference are structurally different from the compounds of Claim 2. The compounds of Claim 2 are not anticipated by, or obvious from, the compounds disclosed in Netzer. Therefore the rejection should be withdrawn.

In view of the foregoing amendments and remarks, the present case is in condition for allowance which action is earnestly solicited.

Respectfully submitted,



Lydia T. McNally
Attorney for Applicant
Reg. No. 36,214
Phone No. (862) 778-7898

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080

Date: September 19, 2008